Introduction and Objectives
To compare transurethral resection only with transurethral resection plus early instillational treatment for non-invasive (Ta, T1) bladder cancer.
Material and Methods
Between 2000–April 2005, 130 patients with Ta and T1 bladder cancers were included in this study. The patients were divided in two groups: Group A including 81 patients who were treated (2000–2002) with transurethral resection of the bladder tumours (TURB). Follow-up:48–80 months (mean 73.4). Goup B including 50 patients with TURB, 1 instillation with 50mg of Epirubicin in the first 6 po hours. Follow-up 24–60 months (mean 43). The patients refused, ignored or were not fit for other adjuvant treatment. The followup were performed every 3 months in the first year, 4 months in the 2nd year, 6 months in the 3th and 4th year, than every year.
In group A, the percent of recurrences according to the risk categories are: 30%; 37.5%; 58%. The total recurrence in group A is 44.4%. In group B,t he percent of recurrences are: 0%; 25.8%; 75%.The total recurrence is 34%. The benefit of 1 instillation with Epirubicin post-TURB is 8.2%, particularly for low risk group is 30. The progression rate in group A are: 0%, 12.5%; 29%. The global progression is 17.2%. In the group B, the progression rate is: 0%; 10%; 25%. The global progression is 12%.
The global benefit regarding recurrence is 10.4%. The study indicated a significant benefit in favor of the early instillational treatment in the low and medium risk group, reducing the percent of tumor recurrence. Regarding progression there is a benefit of 5.2%.
© 2009 European Association of Urology. Published by Elsevier Inc. All rights reserved.